AstraZeneca Plc started the week with a market valuation of about £171 billion ($222 billion). By the close on Thursday it ...

AstraZeneca has beaten analysts’ expectations in its second quarter results, outshining its UK counterpart GlaxoSmithKline, which has been hit by disruption caused by the COVID-19 pandemic.

Like AZ and Amgen, GSK is waiting to reveal the data at an upcoming medical meeting. Despite midstage trial miss, Amgen and ...

And finally, its high-profile China president, Leon Wang, has been detained by authorities over the past week. AstraZeneca has told investors that it does not have clear visibility on the reasons.

AstraZeneca has succeeded in a last-gasp effort to stop its former head of investor relations joining rival UK pharma group GSK, after winning an injunction in the High Court in London.

AstraZeneca's Fasenra (bevacizumab) is set to challenge GSK’s Nucala (mepolizumab) in eosinophilic granulomatosis with ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

It’s been a weekend of love-ins for Big Pharma: first, there was the revelation that European (Swedish-British) firm AstraZeneca and American firm Pfizer had been in talks. Now, Novartis (Swiss) and ...

Analyst Etzer Darout of BMO Capital maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of $89.00.

Here are the 2025 dividend forecasts for FTSE giants Unilever, GSK, and AstraZeneca James Fox has positions in AstraZeneca Plc. The Motley Fool UK has recommended AstraZeneca Plc. Views expressed on ...

AstraZeneca said it will pay up to $2 billion to CSPC Pharmaceutical ... for felzartamab to treat antibody-mediated rejection in kidney transplant recipients. GSK will pay $2.2 billion to settle 93% ...

The FTSE 100 finished 11.85 points, or 0.14%, lower to end the day at 8,172.39. In the US, Wall Street started trading in a ...